Urovant hops across the pond, out-li­cens­ing over­ac­tive blad­der drug to Pierre Fab­re for $75M

Urovant Sci­ences, the for­mer sub­sidiary of Vivek Ra­maswamy’s Roivant Sci­ences, is branch­ing out across the At­lantic in a new li­cens­ing deal.

The Cal­i­for­nia biotech and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER